Patents by Inventor Bruce Bunnell

Bruce Bunnell has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Enhanced osteogenic activity of daidzein analogs on human mesenchymal stem cells
    Patent number: 11098053
    Abstract: Disclosed are daidzein analogs having the formula (I). Also disclosed are compositions, include a disclosed daidzein analogs, methods of preventing or treating bone disease or bone injury and/or stimulating bone growth, in a subject that include administering to the subject an effective amount of disclosed daidzein analog. Disclosed are isolated mesenchymal stem cell that has been altered by treatment a disclosed daidzein analog, daidzein, glycinol, glyceollin I, or glyceollin II, to increase the osteogenic potential of the mesenchymal stem cells.
    Type: Grant
    Filed: April 4, 2014
    Date of Patent: August 24, 2021
    Assignees: THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND, XAVIER UNIVERSITY OF LOUISIANA, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF AGRICULTURE
    Inventors: Amy Strong, Stephen Boue, Matthew Burow, Bruce Bunnell, Quan Jiang, Shilong Zheng, Guangdi Wang
  • Primary mesenchymal stem cells as a vaccine platform
    Patent number: 10472647
    Abstract: Episomally transfected primary mesenchymal stem cells (MSC) express a polypeptide consisting of an antigenic polypeptide (e.g., one or more polypeptides) relating to a pathogen (e.g., one or more virus, bacterium, or parasite). The antigenic polypeptide can have the amino acid sequence of a natural polypeptide from the pathogen or an amino acid sequence differing from the natural sequence by one or more conservative amino acid substitutions. Uses and method for treating or preventing infections with episomally transfected primary MSC also are described.
    Type: Grant
    Filed: November 15, 2013
    Date of Patent: November 12, 2019
    Assignee: The Administrators of the Tulane Educational Fund
    Inventors: Suzanne L. Tomchuck, Elizabeth B. Norton, Robert F. Garry, Bruce Bunnell, John D. Clements
  • Enhanced Osteogenic Activity of Daidzein Analogs on Human Mesenchymal Stem Cells
    Publication number: 20160068542
    Abstract: Disclosed are daidzein analogs having the formula (I). Also disclosed are compositions, include a disclosed daidzein analogs, methods of preventing or treating bone disease or bone injury and/or stimulating bone growth, in a subject that include administering to the subject an effective amount of disclosed daidzein analog. Disclosed are isolated mesenchymal stem cell that has been altered by treatment a disclosed daidzein analog, daidzein, glycinol, glyceollin I, or glyceollin II, to increase the osteogenic potential of the mesenchymal stem cells.
    Type: Application
    Filed: April 4, 2014
    Publication date: March 10, 2016
    Inventors: Zhenzhen SHI, Amy STRONG, Stephen BOUE, Matthew BUROW, Bruce BUNNELL, Quan JIANG, Shilong ZHENG, Guangdi WANG
  • PRIMARY MESENCHYMAL STEM CELLS AS A VACCINE PLATFORM
    Publication number: 20140178422
    Abstract: Episomally transfected primary mesenchymal stem cells (MSC) express a polypeptide consisting of an antigenic polypeptide (e.g., one or more polypeptides) relating to a pathogen (e.g., one or more virus, bacterium, or parasite). The antigenic polypeptide can have the amino acid sequence of a natural polypeptide from the pathogen or an amino acid sequence differing from the natural sequence by one or more conservative amino acid substitutions. Uses and method for treating or preventing infections with episomally transfected primary MSC also are described.
    Type: Application
    Filed: November 15, 2013
    Publication date: June 26, 2014
    Applicant: The Administrators of the Tulane Educational Fund
    Inventors: Suzanne L. Tomchuck, Elizabeth B. Norton, Robert F. Garry, Bruce Bunnell, John D. Clements
  • USE OF ADIPOSE-DERIVED STEM CELLS FOR TREATMENT OF LEUKODYSTROPHIES
    Publication number: 20080095750
    Abstract: The present invention relates to a treatment of a leukodystrophy by administration of an adipose-derived stem cell. Specifically, the present invention relates to the treatment of Krabbe disease with an adipose derived stem cell differentiated to express galactocerebrosidase.
    Type: Application
    Filed: May 9, 2007
    Publication date: April 24, 2008
    Applicants: PENNINGTON BIOMEDICAL RESEARCH CENTER, LOUISIANA STATE UNIVERSITY SYSTEM, TULANE NATIONAL PRIMATE RESEARCH CENTER
    Inventors: Jeffrey Gimble, Bruce Bunnell, Mandi Lopez